Daiichi Sankyo Co. Ltd.

10/22/2023 | Press release | Distributed by Public on 10/22/2023 00:39

Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.